Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals (SYRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,031
  • Shares Outstanding, K 6,300
  • Annual Sales, $ 23,490 K
  • Annual Income, $ -86,560 K
  • 60-Month Beta 1.62
  • Price/Sales 1.43
  • Price/Cash Flow N/A
  • Price/Book 1.08
Trade SYRS with:

Options Overview Details

View History
  • Implied Volatility 372.88% ( -175.50%)
  • Historical Volatility 90.01%
  • IV Percentile 73%
  • IV Rank 25.98%
  • IV High 1,269.81% on 08/12/22
  • IV Low 58.05% on 12/23/21
  • Put/Call Vol Ratio 0.08
  • Today's Volume 57
  • Volume Avg (30-Day) 27
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 10,789
  • Open Int (30-Day) 4,228

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -4.06
  • Number of Estimates 4
  • High Estimate -3.04
  • Low Estimate -5.30
  • Prior Year -4.10
  • Growth Rate Est. (year over year) +0.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.25 +2.86%
on 09/19/22
9.25 -41.62%
on 09/13/22
-2.80 (-34.15%)
since 08/29/22
3-Month
5.25 +2.86%
on 09/19/22
11.00 -50.91%
on 08/04/22
-4.19 (-43.70%)
since 06/29/22
52-Week
5.25 +2.86%
on 09/19/22
48.00 -88.75%
on 10/13/21
-37.80 (-87.50%)
since 09/29/21

Most Recent Stories

More News
Syros Pharmaceuticals, Inc. (SYRS) Upgraded to Buy: What Does It Mean for the Stock?

Syros Pharmaceuticals, Inc. (SYRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SYRS : 5.51 (-0.90%)
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant...

SYRS : 5.51 (-0.90%)
Pre-Market Brief: Stocks Slump As Recessionary Fears Grow

September S&P 500 futures (ESU22) are trending down -1.02% this morning after three major US benchmark indices resumed declines during the regular session as a variety of economic data failed to change...

ESU22 : 3,871.24s (-0.79%)
FDX : 148.82 (-0.78%)
AMZN : 114.72 (-2.79%)
ADBE : 276.44 (-1.76%)
UPS : 166.05 (-0.64%)
SYRS : 5.51 (-0.90%)
TYME : 0.3107 (+8.07%)
GE : 62.57 (-2.93%)
IHG : 48.31 (-3.88%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syros Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

SYRS : 5.51 (-0.90%)
Syros and Tyme Technologies Announce Stockholder Approval of Merger

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special...

SYRS : 5.51 (-0.90%)
TYME : 0.3107 (+8.07%)
Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug

Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.

BMY : 71.77 (-0.40%)
LLY : 329.87 (-1.35%)
SYRS : 5.51 (-0.90%)
IMCR : 43.76 (-2.76%)
Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan...

SYRS : 5.51 (-0.90%)
Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present...

SYRS : 5.51 (-0.90%)
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of...

SYRS : 5.51 (-0.90%)
TYME TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TYME Technologies, Inc. - TYME

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TYME Technologies, Inc. (NasdaqCM: TYME) to...

TYME : 0.3107 (+8.07%)
SYRS : 5.51 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients...

See More

Key Turning Points

3rd Resistance Point 5.95
2nd Resistance Point 5.77
1st Resistance Point 5.67
Last Price 5.51
1st Support Level 5.39
2nd Support Level 5.21
3rd Support Level 5.11

See More

52-Week High 48.00
Fibonacci 61.8% 31.67
Fibonacci 50% 26.63
Fibonacci 38.2% 21.58
Last Price 5.51
52-Week Low 5.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar